915 related articles for article (PubMed ID: 11426650)
1. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
Zucker S; Cao J; Chen WT
Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies.
Folgueras AR; Pendás AM; Sánchez LM; López-Otín C
Int J Dev Biol; 2004; 48(5-6):411-24. PubMed ID: 15349816
[TBL] [Abstract][Full Text] [Related]
3. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
[TBL] [Abstract][Full Text] [Related]
4. The other side of MMPs: protective roles in tumor progression.
Martin MD; Matrisian LM
Cancer Metastasis Rev; 2007 Dec; 26(3-4):717-24. PubMed ID: 17717634
[TBL] [Abstract][Full Text] [Related]
5. MT1-MMP: universal or particular player in angiogenesis?
Genís L; Gálvez BG; Gonzalo P; Arroyo AG
Cancer Metastasis Rev; 2006 Mar; 25(1):77-86. PubMed ID: 16680574
[TBL] [Abstract][Full Text] [Related]
6. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression.
Jodele S; Blavier L; Yoon JM; DeClerck YA
Cancer Metastasis Rev; 2006 Mar; 25(1):35-43. PubMed ID: 16680570
[TBL] [Abstract][Full Text] [Related]
7. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting.
Gialeli C; Theocharis AD; Karamanos NK
FEBS J; 2011 Jan; 278(1):16-27. PubMed ID: 21087457
[TBL] [Abstract][Full Text] [Related]
8. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia.
Klein G; Vellenga E; Fraaije MW; Kamps WA; de Bont ES
Crit Rev Oncol Hematol; 2004 May; 50(2):87-100. PubMed ID: 15157658
[TBL] [Abstract][Full Text] [Related]
9. Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model.
Arlt M; Kopitz C; Pennington C; Watson KL; Krell HW; Bode W; Gansbacher B; Khokha R; Edwards DR; Krüger A
Cancer Res; 2002 Oct; 62(19):5543-50. PubMed ID: 12359766
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review.
Jezierska A; Motyl T
Med Sci Monit; 2009 Feb; 15(2):RA32-40. PubMed ID: 19182722
[TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation.
Hofmann UB; Eggert AA; Blass K; Bröcker EB; Becker JC
Cancer Res; 2003 Dec; 63(23):8221-5. PubMed ID: 14678978
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the regulation of matrix metalloproteinase 2 activation: from basic research to clinical implication (Review).
Yoshizaki T; Sato H; Furukawa M
Oncol Rep; 2002; 9(3):607-11. PubMed ID: 11956636
[TBL] [Abstract][Full Text] [Related]
13. [Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis].
Masson V
Bull Mem Acad R Med Belg; 2006; 161(5):320-6. PubMed ID: 17283905
[TBL] [Abstract][Full Text] [Related]
14. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN.
Tang Y; Kesavan P; Nakada MT; Yan L
Mol Cancer Res; 2004 Feb; 2(2):73-80. PubMed ID: 14985463
[TBL] [Abstract][Full Text] [Related]
15. [Metalloproteinases in tumor progression. Review].
Arvelo F; Cotte C
Invest Clin; 2006 Jun; 47(2):185-205. PubMed ID: 16886780
[TBL] [Abstract][Full Text] [Related]
16. [Extracellular matrix degradation enzymes: important factors in liver metastasis of colorectal cancer and good targets for anticancer metastatic therapy].
Ichikawa Y; Ishikawa T; Tanaka K; Togo S; Shimada H
Nihon Geka Gakkai Zasshi; 2001 May; 102(5):376-80. PubMed ID: 11393999
[TBL] [Abstract][Full Text] [Related]
17. Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice.
Drew AF; Blick TJ; Lafleur MA; Tim EL; Robbie MJ; Rice GE; Quinn MA; Thompson EW
Gynecol Oncol; 2004 Dec; 95(3):437-48. PubMed ID: 15581944
[TBL] [Abstract][Full Text] [Related]
18. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials.
Pavlaki M; Zucker S
Cancer Metastasis Rev; 2003; 22(2-3):177-203. PubMed ID: 12784996
[TBL] [Abstract][Full Text] [Related]
20. [Tumor metastasis and MMP inhibitor].
Sato H
Clin Calcium; 2006 Apr; 16(4):621- 26. PubMed ID: 16582513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
